Fredun Pharmaceuticals Faces Preferential Issue Fund Utilization Deviations Flagged by CARE Ratings
Fredun Pharmaceuticals Ltd · Others (Uncategorized) · 14 Nov 2026, 9:02 pm
Fredun Pharmaceuticals Faces Preferential Issue Fund Utilization Deviations Flagged by CARE Ratings CARE Ratings flagged a 10–25% deviation in Fredun Pharmaceuticals' ₹149.50 cr preferential issue proceeds utilization for the quarter ended 30th Sep'26. Out of ₹128.78 cr received, the monitoring agency reported total utilization at ₹101.34 cr versus ₹97.56 cr claimed by management. Key concerns include non-traceability of source funds due to opening unutilized balance discrepancies in Q2FY27 (₹34.43 cr vs ₹21.47 cr reported in Q1FY27), comingling of funds, and parking proceeds in debit-balance Cash Credit accounts. Management maintains funds were used strictly for approved business objects without diversion.
Original exchange filing (PDF)
More announcements from Fredun Pharmaceuticals Ltd
- Audio Recording Q2 & H1 FY27 Earnings Conference Call of Fredun Pharmaceuticals Limited. · 16 Nov 2026
- Outcome of the Board Meeting of 'Fredun Pharmaceuticals Limited' ('Company') pursuant to Regulation 30 of Schedule III of the SEBI (Listing Obligations & Disclosure Requirements) Regulations, 2015. · 14 Nov 2026
- Statement of Deviation or Variation For the Quarter Ended September 30, 2026 for the Funds raised through Preferential Issue. · 14 Nov 2026
- Intimation of Earnings Conference Call for the Quarter Q2 of FY27 · 16 Nov 2026
- Press Release · 06 Nov 2026
- Approval for National Stock Exchange of India Limited (NSE) Listing Application. · 05 Nov 2026
- Financial results for the quarter ended 30th September, 2026. · 05 Nov 2026
- Outcome of the Board Meeting dated 05th November, 2026. · 05 Nov 2026
